Ngā hua rapu kaituhi

1

Best of AASLD 2006 mā Reau, Nancy

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
2

HCV testing and linkage to care: Expanding access mā Reau, Nancy

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
3

Pangenotypic regimens and the next generation hepatitis C virus therapy mā Reau, Nancy S.

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
4

Chronic Viral Hepatitis: Current Management and Future Directions mā Do, Albert, Reau, Nancy S.

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
5

Disseminated AIDS-Related Kaposi Sarcoma Immune Reconstitution Inflammatory Syndrome With Infiltrative Liver Disease mā Van, Jeremy, Reau, Nancy

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
6

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? mā Janardhan, Sujit V, Reau, Nancy S

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
7

A pregnant patient with a positive hepatitis B surface antigen mā Mufti, Arjmand Rasool, Reau, Nancy

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
8

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: A Patient‐Friendly Summary of the 2019 AASLD Guidelines mā L. Volk, Michael, Reau, Nancy

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
9

Clinical Liver Disease: Introducing hot topics in hepatology mā VanWagner, Lisa B., Reau, Nancy

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
10

Considering direct-acting antivirals to cure hepatitis C virus during pregnancy: is this the last treatment frontier? mā Kushner, Tatyana, Cafardi, John, Reau, Nancy

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
11

Acquired Hemophagocytic Lymphohistiocytosis Associated With Disseminated Herpes Simplex Virus in Immunocompetent Host mā Schwartz, Michael, O'Brien, Courtney, Raya, Nischal, Reau, Nancy

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
12

Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States mā Chaillon, Antoine, Rand, Elizabeth B, Reau, Nancy, Martin, Natasha K

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
13

Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy mā Reau, Nancy, Vekeman, Francis, Wu, Eric, Bao, Yanjun, Gonzalez, Yuri Sanchez

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
14

Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States mā Chaillon, Antoine, Wynn, Adriane, Kushner, Tatyana, Reau, Nancy, Martin, Natasha K

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
15

Early Predictors of Anemia in Patients with Hepatitis C Genotype 1 Treated with Peginterferon alfa-2a (40KD) plus Ribavirin mā Reau, Nancy, Hadziyannis, Stephanos J., Messinger, Diethelm, Fried, Michael W., Jensen, Donald M.

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
16

Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States mā Hoenigl, Martin, Abramovitz, Daniela, Flores Ortega, Ricardo E, Martin, Natasha K, Reau, Nancy

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
17

Estimating the Year Each State in the United States Will Achieve the World Health Organization’s Elimination Targets for Hepatitis C mā Sulkowski, Mark, Cheng, Wei-Han, Marx, Steven, Sanchez Gonzalez, Yuri, Strezewski, John, Reau, Nancy

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
18

Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis mā Sauk, Jenny, Jensen, Donald M., Mohanty, Smruti R., Reau, Nancy, Reddy, K. Gautham, Te, Helen S.

I whakaputaina 2006

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
19

Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease mā Desai, Archita P., Reau, Nancy, Reddy, K. Gautham, Te, Helen S., Mohanty, Smruti, Satoskar, Rohit, DeVoss, Amanda, Jensen, Donald

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:
20

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents mā Shiffman, Mitchell L, Rustgi, Vinod, Bennett, Michael, Forns, Xavier, Asselah, Tarik, Planas Vila, Ramon, Liu, Li, Pedrosa, Marcos, Moller, Jonathan, Reau, Nancy

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Text

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Reau, Nancy

Best of AASLD 2006 mā Reau, Nancy

HCV testing and linkage to care: Expanding access mā Reau, Nancy

Pangenotypic regimens and the next generation hepatitis C virus therapy mā Reau, Nancy S.

Chronic Viral Hepatitis: Current Management and Future Directions mā Do, Albert, Reau, Nancy S.

Disseminated AIDS-Related Kaposi Sarcoma Immune Reconstitution Inflammatory Syndrome With Infiltrative Liver Disease mā Van, Jeremy, Reau, Nancy

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? mā Janardhan, Sujit V, Reau, Nancy S

A pregnant patient with a positive hepatitis B surface antigen mā Mufti, Arjmand Rasool, Reau, Nancy

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: A Patient‐Friendly Summary of the 2019 AASLD Guidelines mā L. Volk, Michael, Reau, Nancy

Clinical Liver Disease: Introducing hot topics in hepatology mā VanWagner, Lisa B., Reau, Nancy

Considering direct-acting antivirals to cure hepatitis C virus during pregnancy: is this the last treatment frontier? mā Kushner, Tatyana, Cafardi, John, Reau, Nancy

Acquired Hemophagocytic Lymphohistiocytosis Associated With Disseminated Herpes Simplex Virus in Immunocompetent Host mā Schwartz, Michael, O'Brien, Courtney, Raya, Nischal, Reau, Nancy

Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States mā Chaillon, Antoine, Rand, Elizabeth B, Reau, Nancy, Martin, Natasha K

Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy mā Reau, Nancy, Vekeman, Francis, Wu, Eric, Bao, Yanjun, Gonzalez, Yuri Sanchez

Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States mā Chaillon, Antoine, Wynn, Adriane, Kushner, Tatyana, Reau, Nancy, Martin, Natasha K

Early Predictors of Anemia in Patients with Hepatitis C Genotype 1 Treated with Peginterferon alfa-2a (40KD) plus Ribavirin mā Reau, Nancy, Hadziyannis, Stephanos J., Messinger, Diethelm, Fried, Michael W., Jensen, Donald M.

Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States mā Hoenigl, Martin, Abramovitz, Daniela, Flores Ortega, Ricardo E, Martin, Natasha K, Reau, Nancy

Estimating the Year Each State in the United States Will Achieve the World Health Organization’s Elimination Targets for Hepatitis C mā Sulkowski, Mark, Cheng, Wei-Han, Marx, Steven, Sanchez Gonzalez, Yuri, Strezewski, John, Reau, Nancy

Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis mā Sauk, Jenny, Jensen, Donald M., Mohanty, Smruti R., Reau, Nancy, Reddy, K. Gautham, Te, Helen S.

Ngā utauta rapu: